Adapalene 0.3% Gel Shows Efficacy for the Treatment of Atrophic Acne Scars

Manisha J. Loss, Sherry Leung, Anna Lien-Lun Chien, Nabil Kerrouche, Alexander H. Fischer, Sewon Kang

Research output: Contribution to journalArticle

Abstract

Introduction: Scarring is an unfortunate clinical outcome of acne. Current treatment options for atrophic acne scars are dominated by non-pharmacological, invasive procedures which may not be suitable or affordable to all patients. This phase II, single-center, open-label, exploratory study assessed the efficacy, safety and subject-reported outcomes of adapalene 0.3% gel in the treatment of atrophic acne scars. Methods: The study included subjects aged 18–50 years with past history of acne and moderate to severe facial atrophic acne scars. Subjects received adapalene 0.3% gel once daily for the first 4 weeks and twice daily for the following 20 weeks. Assessments were performed at baseline, day 10 and weeks 4, 8, 16 and 24, and at post-treatment follow-ups (weeks 36 and 48–72). Results: At week 24, investigator and subject assessments reported improvement in skin texture/atrophic scars in 50% and > 80% of subjects, respectively. Subjects were satisfied with the treatment and reported improvements in quality of life. Conclusion: Daily use of adapalene 0.3% gel for the treatment of atrophic acne scars showed promising clinical efficacy, a favorable tolerability profile, and improvement in quality of life. Funding: Nestlé Skin Health–Galderma R&D. Trial Registration: ClinicalTrials.gov Identifier NCT01213199.

Original languageEnglish (US)
Pages (from-to)245-257
Number of pages13
JournalDermatology and Therapy
Volume8
Issue number2
DOIs
StatePublished - Jun 1 2018

Fingerprint

Acne Vulgaris
Cicatrix
Gels
Quality of Life
Therapeutics
Skin
Adapalene
Research Personnel
Safety

Keywords

  • Acne
  • Adapalene
  • Atrophic scars
  • Molecular markers
  • Scarring
  • Skin texture
  • Subject-reported outcome
  • Topical retinoids

ASJC Scopus subject areas

  • Dermatology

Cite this

Adapalene 0.3% Gel Shows Efficacy for the Treatment of Atrophic Acne Scars. / Loss, Manisha J.; Leung, Sherry; Chien, Anna Lien-Lun; Kerrouche, Nabil; Fischer, Alexander H.; Kang, Sewon.

In: Dermatology and Therapy, Vol. 8, No. 2, 01.06.2018, p. 245-257.

Research output: Contribution to journalArticle

Loss, Manisha J. ; Leung, Sherry ; Chien, Anna Lien-Lun ; Kerrouche, Nabil ; Fischer, Alexander H. ; Kang, Sewon. / Adapalene 0.3% Gel Shows Efficacy for the Treatment of Atrophic Acne Scars. In: Dermatology and Therapy. 2018 ; Vol. 8, No. 2. pp. 245-257.
@article{3dfb470b1b5c40d3ac6af2ab52fded8b,
title = "Adapalene 0.3{\%} Gel Shows Efficacy for the Treatment of Atrophic Acne Scars",
abstract = "Introduction: Scarring is an unfortunate clinical outcome of acne. Current treatment options for atrophic acne scars are dominated by non-pharmacological, invasive procedures which may not be suitable or affordable to all patients. This phase II, single-center, open-label, exploratory study assessed the efficacy, safety and subject-reported outcomes of adapalene 0.3{\%} gel in the treatment of atrophic acne scars. Methods: The study included subjects aged 18–50 years with past history of acne and moderate to severe facial atrophic acne scars. Subjects received adapalene 0.3{\%} gel once daily for the first 4 weeks and twice daily for the following 20 weeks. Assessments were performed at baseline, day 10 and weeks 4, 8, 16 and 24, and at post-treatment follow-ups (weeks 36 and 48–72). Results: At week 24, investigator and subject assessments reported improvement in skin texture/atrophic scars in 50{\%} and > 80{\%} of subjects, respectively. Subjects were satisfied with the treatment and reported improvements in quality of life. Conclusion: Daily use of adapalene 0.3{\%} gel for the treatment of atrophic acne scars showed promising clinical efficacy, a favorable tolerability profile, and improvement in quality of life. Funding: Nestl{\'e} Skin Health–Galderma R&D. Trial Registration: ClinicalTrials.gov Identifier NCT01213199.",
keywords = "Acne, Adapalene, Atrophic scars, Molecular markers, Scarring, Skin texture, Subject-reported outcome, Topical retinoids",
author = "Loss, {Manisha J.} and Sherry Leung and Chien, {Anna Lien-Lun} and Nabil Kerrouche and Fischer, {Alexander H.} and Sewon Kang",
year = "2018",
month = "6",
day = "1",
doi = "10.1007/s13555-018-0231-8",
language = "English (US)",
volume = "8",
pages = "245--257",
journal = "Dermatology and Therapy",
issn = "2190-9172",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Adapalene 0.3% Gel Shows Efficacy for the Treatment of Atrophic Acne Scars

AU - Loss, Manisha J.

AU - Leung, Sherry

AU - Chien, Anna Lien-Lun

AU - Kerrouche, Nabil

AU - Fischer, Alexander H.

AU - Kang, Sewon

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Introduction: Scarring is an unfortunate clinical outcome of acne. Current treatment options for atrophic acne scars are dominated by non-pharmacological, invasive procedures which may not be suitable or affordable to all patients. This phase II, single-center, open-label, exploratory study assessed the efficacy, safety and subject-reported outcomes of adapalene 0.3% gel in the treatment of atrophic acne scars. Methods: The study included subjects aged 18–50 years with past history of acne and moderate to severe facial atrophic acne scars. Subjects received adapalene 0.3% gel once daily for the first 4 weeks and twice daily for the following 20 weeks. Assessments were performed at baseline, day 10 and weeks 4, 8, 16 and 24, and at post-treatment follow-ups (weeks 36 and 48–72). Results: At week 24, investigator and subject assessments reported improvement in skin texture/atrophic scars in 50% and > 80% of subjects, respectively. Subjects were satisfied with the treatment and reported improvements in quality of life. Conclusion: Daily use of adapalene 0.3% gel for the treatment of atrophic acne scars showed promising clinical efficacy, a favorable tolerability profile, and improvement in quality of life. Funding: Nestlé Skin Health–Galderma R&D. Trial Registration: ClinicalTrials.gov Identifier NCT01213199.

AB - Introduction: Scarring is an unfortunate clinical outcome of acne. Current treatment options for atrophic acne scars are dominated by non-pharmacological, invasive procedures which may not be suitable or affordable to all patients. This phase II, single-center, open-label, exploratory study assessed the efficacy, safety and subject-reported outcomes of adapalene 0.3% gel in the treatment of atrophic acne scars. Methods: The study included subjects aged 18–50 years with past history of acne and moderate to severe facial atrophic acne scars. Subjects received adapalene 0.3% gel once daily for the first 4 weeks and twice daily for the following 20 weeks. Assessments were performed at baseline, day 10 and weeks 4, 8, 16 and 24, and at post-treatment follow-ups (weeks 36 and 48–72). Results: At week 24, investigator and subject assessments reported improvement in skin texture/atrophic scars in 50% and > 80% of subjects, respectively. Subjects were satisfied with the treatment and reported improvements in quality of life. Conclusion: Daily use of adapalene 0.3% gel for the treatment of atrophic acne scars showed promising clinical efficacy, a favorable tolerability profile, and improvement in quality of life. Funding: Nestlé Skin Health–Galderma R&D. Trial Registration: ClinicalTrials.gov Identifier NCT01213199.

KW - Acne

KW - Adapalene

KW - Atrophic scars

KW - Molecular markers

KW - Scarring

KW - Skin texture

KW - Subject-reported outcome

KW - Topical retinoids

UR - http://www.scopus.com/inward/record.url?scp=85044396621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044396621&partnerID=8YFLogxK

U2 - 10.1007/s13555-018-0231-8

DO - 10.1007/s13555-018-0231-8

M3 - Article

C2 - 29549598

AN - SCOPUS:85044396621

VL - 8

SP - 245

EP - 257

JO - Dermatology and Therapy

JF - Dermatology and Therapy

SN - 2190-9172

IS - 2

ER -